Real-world study shows inconsistency in haemophilia diagnosis rates

  • Many practitioners are aware that haemophilia is underdiagnosed; a real-world evidence study observed diagnosis rates varying in haemophilia A (16-47%) and haemophilia B (34-65%), showing an unmet need for more accurate and prevalent testing
  • Many patients with haemophilia die before adulthood due to inadequate treatment; even with sufficient treatment, life expectancy in males is approximately 10 years less than their healthy counterparts

Click here and here to learn more

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

ref: FEB2020BR001